New York Univ., NY. Reviews current clinical studies on transfusion-associated immunomodulation (TRIM) in order to provide a better understanding of the debates over the extent of its deleterious effects. This, in turn, leads into a discussion of possible mandated universal leukocyte reduction in the U.S.